Morning Buzz: Prana Biotechnology (PRAN), Heron Therapeutics (HRTX), Vascular Biogenics (VBLT), Clovis Oncology (CLVS)

Prana Biotechnology Limited (PRAN) shares surged 19.26% to $1.61 in early trading following the company’s announcement that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington’s disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington’s disease.

Shares of Heron Therapeutics, Inc. (HRTX) are up $1.93, or over 9.77%, at $21.69. We are not seeing any news or rumors to account for the move, but would note that the company recently entered into a 7 year Commercial Manufacturing Services Agreement for SUSTOL with Lifecore Biomedical.

Vascular Biogenics Ltd. (VBLT) shares were  up 11.80% to $9.00 as of 9:31 a.m. ET on news of positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111. The company said data showed a statistically significant overall survival benefit in patients treated with VB-111.

“We are very pleased to see a statistically significant overall survival benefit in this more mature data set, with median overall survival extended to 16 months in patients receiving VB-111 followed by VB-111 in combination with bevacizumab,” commented Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics.

Clovis Oncology, Inc. (CLVS) shares declined 6.00% to $86.89 in morning trading following the company’s updated findings from its Phase 2 clinical study of rociletinib (CO-1686).

Be the first to comment

Leave a Reply

Your email address will not be published.


*